The Chemours Company (NYSE:CC) Receives Average Recommendation of “Hold” from Analysts

The Chemours Company (NYSE:CC) has been given a consensus rating of “Hold” by the eight analysts that are presently covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $24.88.

CC has been the subject of several research reports. BMO Capital Markets raised their price target on Chemours from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, October 7th. Royal Bank of Canada reduced their target price on shares of Chemours from $28.00 to $25.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. UBS Group decreased their price target on shares of Chemours from $30.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Barclays raised their price objective on shares of Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Finally, The Goldman Sachs Group decreased their target price on Chemours from $29.00 to $23.00 and set a “neutral” rating on the stock in a research report on Tuesday, September 3rd.

Chemours Stock Performance

Shares of CC stock opened at $21.63 on Wednesday. The stock has a market cap of $3.23 billion, a P/E ratio of 43.26 and a beta of 1.80. The company has a fifty day moving average price of $19.77 and a two-hundred day moving average price of $21.19. Chemours has a one year low of $15.10 and a one year high of $32.70. The company has a debt-to-equity ratio of 6.05, a current ratio of 1.73 and a quick ratio of 0.92.

Chemours (NYSE:CC) last posted its quarterly earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.32 by $0.08. The business had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.44 billion. Chemours had a return on equity of 29.48% and a net margin of 1.34%. Chemours’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter last year, the company posted $0.64 earnings per share. As a group, equities analysts predict that Chemours will post 1.35 EPS for the current year.

Chemours Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Friday, November 15th will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 4.62%. The ex-dividend date is Friday, November 15th. Chemours’s dividend payout ratio is currently 200.00%.

Insider Buying and Selling at Chemours

In related news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total transaction of $154,800.00. Following the sale, the senior vice president now owns 16,645 shares in the company, valued at approximately $343,552.80. This trade represents a 31.06 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.47% of the company’s stock.

Institutional Investors Weigh In On Chemours

Several institutional investors and hedge funds have recently added to or reduced their stakes in CC. M&T Bank Corp lifted its holdings in shares of Chemours by 4.1% in the third quarter. M&T Bank Corp now owns 510,343 shares of the specialty chemicals company’s stock worth $10,370,000 after acquiring an additional 20,122 shares during the last quarter. Geode Capital Management LLC boosted its position in Chemours by 1.2% in the third quarter. Geode Capital Management LLC now owns 2,491,748 shares of the specialty chemicals company’s stock valued at $50,646,000 after buying an additional 28,803 shares in the last quarter. Barclays PLC grew its stake in shares of Chemours by 28.4% during the third quarter. Barclays PLC now owns 107,549 shares of the specialty chemicals company’s stock worth $2,185,000 after buying an additional 23,766 shares during the last quarter. Vision One Management Partners LP acquired a new position in shares of Chemours during the third quarter worth $28,252,000. Finally, Two Sigma Advisers LP boosted its holdings in shares of Chemours by 9.4% during the 3rd quarter. Two Sigma Advisers LP now owns 503,100 shares of the specialty chemicals company’s stock valued at $10,223,000 after acquiring an additional 43,200 shares in the last quarter. 76.26% of the stock is currently owned by institutional investors.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.